What is Cagrisema?
Cagrisema combines two clinically researched compounds:
-
Semaglutide (GLP-1) – slows gastric emptying, regulates appetite, reduces cravings, and helps maintain stable blood sugar after meals.
-
Cagrilintide (Amylin analogue) – promotes satiety, regulates appetite, supports insulin control, and aids fat loss.
Together, these compounds mimic natural metabolic hormones and have been shown in studies to help participants lose up to 22.5% of their body weight.
Key Benefits
- Promotes effective and sustainable weight loss
- Helps control appetite and reduce food cravings
- Improves blood sugar regulation for better metabolic health
- Convenient once-weekly pre-filled pen
- Supports long-term weight management and lifestyle change
Dosage & Usage Guide
The Cagrisema 12mg Pen features a built-in dosage selector for gradual adjustment:
-
Week 1–4: 0.25mg
-
Week 5–8: 0.5mg
-
Week 9–12: 0.75mg
-
Week 13–16: 1mg
-
From Week 17 onwards: 1.2mg
This slow increase ensures optimal tolerance and effectiveness. Continue at a dosage that works well for you, as long as appetite control and weight loss progress are maintained.
Important Information & Safety
Cagrisema is currently under investigation in the global REDEFINE and REIMAGINE clinical trials for weight management and type 2 diabetes. While results show strong effectiveness, it has not yet been formally approved as a combined treatment by Novo Nordisk.
Not suitable for pregnant or breastfeeding individuals, or those with contraindicated conditions.
Why Choose Body Pharm Cagrisema?
With Body Pharm, you are assured of high purity peptides, precision dosing, and reliable quality. The Cagrisema 12mg Pen offers South Africans access to advanced weight management technology that works in harmony with a healthy lifestyle for lasting results.
Disclaimer: This product is investigational and intended for research and personal use under professional guidance. It is not yet approved as a standard medical treatment.
